2023
Serum BDNF levels are involved in the diagnosis and treatment response in patients with PD
Li R, Li J, Liu Y, Li D, Chu L, Zhang J, Luo X, Zhang Y. Serum BDNF levels are involved in the diagnosis and treatment response in patients with PD. Journal Of Affective Disorders 2023, 327: 31-37. PMID: 36739005, DOI: 10.1016/j.jad.2023.01.107.Peer-Reviewed Original ResearchConceptsBaseline serum BDNF levelsSerum BDNF levelsBrain-derived neurotrophic factorState-Trait Anxiety InventoryBDNF levelsPanic disorderTrait anxietyHAMA-14PD patientsHealthy controlsBrain-derived neurotrophic factor serum levelsDiagnosis of panic disorderTreatment response to escitalopramHamilton Anxiety Rating ScaleResponse to escitalopramAnxiety Rating ScaleTreatment responseEscitalopram treatmentAnxiety symptomsNeuropsychological testsNinety PD patientsState-TraitAnxiety InventoryRating ScaleWeeks of treatment
2022
Association between plasma levels of BDNF and GDNF and the diagnosis, treatment response in first-episode MDD
Liu X, Li P, Ma X, Zhang J, Sun X, Luo X, Zhang Y. Association between plasma levels of BDNF and GDNF and the diagnosis, treatment response in first-episode MDD. Journal Of Affective Disorders 2022, 315: 190-197. PMID: 35908604, DOI: 10.1016/j.jad.2022.07.041.Peer-Reviewed Original ResearchConceptsAntidepressant treatmentPlasma levelsGDNF levelsMATRICS Consensus Cognitive BatteryMDD patientsHealthy controlsDepression severityWeeks antidepressant treatmentFirst-episode depressionPeripheral plasma levelsPeripheral venous bloodWeeks of treatmentDiagnosis of MDDDecreased plasma levelsHAMA-14Plasma BDNFAntidepressant medicationClinical symptomsHDRS-17Venous bloodCognitive dysfunctionPlasma concentrationsTreatment responseConsensus Cognitive BatteryPatients
2017
Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder
He Q, Yuan Z, Liu Y, Zhang J, Yan H, Shen L, Luo X, Zhang Y. Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. Pharmacogenetics And Genomics 2017, 27: 279-284. PMID: 28614176, DOI: 10.1097/fpc.0000000000000290.Peer-Reviewed Original Research
2016
The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder
Cao Y, Shen J, Li W, Zhang Y, Guo X, Li C, Zhang Y, Luo X. The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder. Asia-Pacific Psychiatry 2016, 8: 309-311. PMID: 27015764, PMCID: PMC5035708, DOI: 10.1111/appy.12240.Peer-Reviewed Original ResearchConceptsClinical remissionChinese patientsSymptom trajectoriesUnipolar major depressive disorderMajor depressive disorder symptomsWeeks of assessmentMajor depressive disorderTreatment of fluoxetineDepressive disorder symptomsDepressive disorderTreatment responseProminent symptomWeek 1Psychomotor retardationRemissionSymptom severityPatientsDisorder symptomsFluoxetineSymptomsSeverityWeeksTreatmentOutpatientsShow heterogeneity